Fairvalue-Calculator Fairvalue-Calculator
EN DE

Demant A/S (DEMANT) Fair Value & Analysis

Healthcare · DK · Market cap 52.8B DKK

Pricekr 255.80
Fair Valuekr 161.17
Upside-37.0%
Quality95/100
Evidence: High Range kr 106.55 – kr 220.26

Fair value as of: Jun 24, 2026

Analysis

Demant A/S (DEMANT) currently trades at kr 255.80, while our model-based Fair Value estimate is kr 161.17 — implying the stock looks roughly 37.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -84% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -83% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Demant A/S (DEMANT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 161.17 versus a price of kr 255.80 — about −37% (overvalued). Model-based estimate, not financial advice.
What is the fair value of DEMANT?
Our 21-model fair value for Demant A/S is kr 161.17 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 255.80.
What is the quality score of DEMANT?
Demant A/S has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.